News
FDA could make it harder to get young kids a COVID shot
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children younger than 5 years old, a move that would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.
Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Dealbreaker on MSN2d
BioNTech to Pay $740M-Plus to Settle mRNA Patent Disputes, Smooth $1.25 Billion Deal
In litigation over the past two years, CureVac alleged the BioNTech and Pfizer vaccine for Covid-19 infringed CureVac patents based on its more than two decades of mRNA research. Under terms of the ...
The Manila Times on MSN11d
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...
Pfizer (PFE-1.64%) and BioNTech (BNTX-1.15%) together pulled off one of the greatest accomplishments in medical history by developing a safe and highly effective COVID-19 vaccine in only a matter ...
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback